698 related articles for article (PubMed ID: 23238683)
21. Overcoming CML acquired resistance by specific inhibition of Aurora A kinase in the KCL-22 cell model.
Yuan H; Wang Z; Zhang H; Roth M; Bhatia R; Chen WY
Carcinogenesis; 2012 Feb; 33(2):285-93. PubMed ID: 22116466
[TBL] [Abstract][Full Text] [Related]
22. Aberrant signalling by protein kinase CK2 in imatinib-resistant chronic myeloid leukaemia cells: biochemical evidence and therapeutic perspectives.
Borgo C; Cesaro L; Salizzato V; Ruzzene M; Massimino ML; Pinna LA; Donella-Deana A
Mol Oncol; 2013 Dec; 7(6):1103-15. PubMed ID: 24012109
[TBL] [Abstract][Full Text] [Related]
23. Structural mechanism of the Pan-BCR-ABL inhibitor ponatinib (AP24534): lessons for overcoming kinase inhibitor resistance.
Zhou T; Commodore L; Huang WS; Wang Y; Thomas M; Keats J; Xu Q; Rivera VM; Shakespeare WC; Clackson T; Dalgarno DC; Zhu X
Chem Biol Drug Des; 2011 Jan; 77(1):1-11. PubMed ID: 21118377
[TBL] [Abstract][Full Text] [Related]
24. PBA2, a novel inhibitor of imatinib-resistant BCR-ABL T315I mutation in chronic myeloid leukemia.
Gupta P; Kathawala RJ; Wei L; Wang F; Wang X; Druker BJ; Fu LW; Chen ZS
Cancer Lett; 2016 Dec; 383(2):220-229. PubMed ID: 27720778
[TBL] [Abstract][Full Text] [Related]
25. Dihydroartemisinin inhibits the Bcr/Abl oncogene at the mRNA level in chronic myeloid leukemia sensitive or resistant to imatinib.
Lee J; Shen P; Zhang G; Wu X; Zhang X
Biomed Pharmacother; 2013 Mar; 67(2):157-63. PubMed ID: 23201011
[TBL] [Abstract][Full Text] [Related]
26. Combination therapy with copanlisib and ABL tyrosine kinase inhibitors against Philadelphia chromosome-positive resistant cells.
Okabe S; Tauchi T; Tanaka Y; Sakuta J; Ohyashiki K
Oncotarget; 2016 Aug; 7(33):53116-53126. PubMed ID: 27437766
[TBL] [Abstract][Full Text] [Related]
27. MEK1/2 inhibitors sensitize Bcr/Abl+ human leukemia cells to the dual Abl/Src inhibitor BMS-354/825.
Nguyen TK; Rahmani M; Harada H; Dent P; Grant S
Blood; 2007 May; 109(9):4006-15. PubMed ID: 17218385
[TBL] [Abstract][Full Text] [Related]
28. Ponatinib circumvents all types of imatinib resistance in chronic myelogenous leukemia cell lines.
Dufies M; Cassuto O; Jacquel A; Robert G; Auberger P
Cell Cycle; 2013 Jun; 12(11):1645-6. PubMed ID: 23673326
[No Abstract] [Full Text] [Related]
29. CDK4/CDK6 inhibition as a novel strategy to suppress the growth and survival of BCR-ABL1
Schneeweiss-Gleixner M; Byrgazov K; Stefanzl G; Berger D; Eisenwort G; Lucini CB; Herndlhofer S; Preuner S; Obrova K; Pusic P; Witzeneder N; Greiner G; Hoermann G; Sperr WR; Lion T; Deininger M; Valent P; Gleixner KV
EBioMedicine; 2019 Dec; 50():111-121. PubMed ID: 31761618
[TBL] [Abstract][Full Text] [Related]
30. AP24534, a pan-BCR-ABL inhibitor for chronic myeloid leukemia, potently inhibits the T315I mutant and overcomes mutation-based resistance.
O'Hare T; Shakespeare WC; Zhu X; Eide CA; Rivera VM; Wang F; Adrian LT; Zhou T; Huang WS; Xu Q; Metcalf CA; Tyner JW; Loriaux MM; Corbin AS; Wardwell S; Ning Y; Keats JA; Wang Y; Sundaramoorthi R; Thomas M; Zhou D; Snodgrass J; Commodore L; Sawyer TK; Dalgarno DC; Deininger MW; Druker BJ; Clackson T
Cancer Cell; 2009 Nov; 16(5):401-12. PubMed ID: 19878872
[TBL] [Abstract][Full Text] [Related]
31. Philadelphia-positive patients who already harbor imatinib-resistant Bcr-Abl kinase domain mutations have a higher likelihood of developing additional mutations associated with resistance to second- or third-line tyrosine kinase inhibitors.
Soverini S; Gnani A; Colarossi S; Castagnetti F; Abruzzese E; Paolini S; Merante S; Orlandi E; de Matteis S; Gozzini A; Iacobucci I; Palandri F; Gugliotta G; Papayannidis C; Poerio A; Amabile M; Cilloni D; Rosti G; Baccarani M; Martinelli G
Blood; 2009 Sep; 114(10):2168-71. PubMed ID: 19589924
[TBL] [Abstract][Full Text] [Related]
32. BCR-ABL1-independent PI3Kinase activation causing imatinib-resistance.
Quentmeier H; Eberth S; Romani J; Zaborski M; Drexler HG
J Hematol Oncol; 2011 Feb; 4():6. PubMed ID: 21299849
[TBL] [Abstract][Full Text] [Related]
33. Anthelmintic niclosamide suppresses transcription of BCR-ABL fusion oncogene via disabling Sp1 and induces apoptosis in imatinib-resistant CML cells harboring T315I mutant.
Jin B; Wang C; Shen Y; Pan J
Cell Death Dis; 2018 Jan; 9(2):68. PubMed ID: 29358661
[TBL] [Abstract][Full Text] [Related]
34. Ever-advancing chronic myeloid leukemia treatment.
Kimura S; Ando T; Kojima K
Int J Clin Oncol; 2014 Feb; 19(1):3-9. PubMed ID: 24258348
[TBL] [Abstract][Full Text] [Related]
35. Simultaneous targeting of Aurora kinases and Bcr-Abl kinase by the small molecule inhibitor PHA-739358 is effective against imatinib-resistant BCR-ABL mutations including T315I.
Gontarewicz A; Balabanov S; Keller G; Colombo R; Graziano A; Pesenti E; Benten D; Bokemeyer C; Fiedler W; Moll J; Brümmendorf TH
Blood; 2008 Apr; 111(8):4355-64. PubMed ID: 18268096
[TBL] [Abstract][Full Text] [Related]
36. Preclinical development of a novel BCR-ABL T315I inhibitor against chronic myeloid leukemia.
Gupta P; Zhang GN; Barbuti AM; Zhang X; Karadkhelkar N; Zhou J; Ding K; Pan J; Yoganathan S; Yang DH; Chen ZS
Cancer Lett; 2020 Mar; 472():132-141. PubMed ID: 31837444
[TBL] [Abstract][Full Text] [Related]
37. The BCR-ABL35INS insertion/truncation mutant is kinase-inactive and does not contribute to tyrosine kinase inhibitor resistance in chronic myeloid leukemia.
O'Hare T; Zabriskie MS; Eide CA; Agarwal A; Adrian LT; You H; Corbin AS; Yang F; Press RD; Rivera VM; Toplin J; Wong S; Deininger MW; Druker BJ
Blood; 2011 Nov; 118(19):5250-4. PubMed ID: 21908430
[TBL] [Abstract][Full Text] [Related]
38. Targets and effectors of the cellular response to aurora kinase inhibitor MK-0457 (VX-680) in imatinib sensitive and resistant chronic myelogenous leukemia.
Donato NJ; Fang D; Sun H; Giannola D; Peterson LF; Talpaz M
Biochem Pharmacol; 2010 Mar; 79(5):688-97. PubMed ID: 19874801
[TBL] [Abstract][Full Text] [Related]
39. Pristimerin induces apoptosis in imatinib-resistant chronic myelogenous leukemia cells harboring T315I mutation by blocking NF-kappaB signaling and depleting Bcr-Abl.
Lu Z; Jin Y; Chen C; Li J; Cao Q; Pan J
Mol Cancer; 2010 May; 9():112. PubMed ID: 20482842
[TBL] [Abstract][Full Text] [Related]
40. Loss of response to imatinib: mechanisms and management.
Shah NP
Hematology Am Soc Hematol Educ Program; 2005; ():183-7. PubMed ID: 16304378
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
